1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Massachusetts >
  6. VectivBio Acquires Comet Therapeutics

M&A Deal Summary

VectivBio Acquires Comet Therapeutics

On August 31, 2021, VectivBio acquired life science company Comet Therapeutics

Acquisition Highlights
  • This is VectivBio’s 1st transaction in the Life Science sector.
  • This is VectivBio’s 1st transaction in the United States.
  • This is VectivBio’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2021-08-31
Target Comet Therapeutics
Sector Life Science
Buyer(s) VectivBio
Deal Type Add-on Acquisition

Target

Comet Therapeutics

Cambridge, Massachusetts, United States
Comet Therapeutics is a privately held company that has been developing drugs to address previously untreatable Inherited Metabolic Diseases. Comet Therapeutics was formed in 2018 and is based in Cambridge, Massachusetts.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

VectivBio

Basel, Switzerland
Category Company
Founded 2019
Sector Life Science
Revenue 27M USD (2022)
DESCRIPTION

VectivBio is a clinical-stage biotechnology company focused on rare diseases with well-defined biology that can be targeted with transformational therapeutics. VectivBio was formed in 2019 as a spinout from Therachon, a biotechnology company acquired by Pfizer, Inc., for its program in achondroplasia, with the ambition to continue to have an impact on people’s lives by bringing transformational medicines to patients with serious rare conditions. VectivBio is based in Basel, Switzerland.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Add-on Acquisition M&A Deals 1 of 1
State: Massachusetts M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2021 M&A 1 of 1
Mergr

Solution for

Product

Company

Legal